Table 1.
The most common biomarkers used to detect different cancer types and their clinical use.
| Biomarker | Cancer Type | Clinical Use |
|---|---|---|
| NMP22 | Bladder | Screening and monitoring |
| Modified nucleosides | Diagnosis, screening, and monitoring | |
| CA-125 | Breast, Ovarian | Monitoring |
| CEA | Colon | Monitoring |
| Modified nucleosides | Diagnosis, screening, and monitoring | |
| AFP | Liver | Diagnosis |
| Bilirubin | Diagnosis | |
| Bilirubin | Lung | Diagnosis |
| Neopterin | Diagnosis and monitoring | |
| PSA | Prostate | Screening and monitoring |
| Calcitonin | Thyroid | Diagnosis, prognosis, and screening |
NMP22: nuclear matrix protein 22; CA-125: cancer antigen 125; CEA: carcinoembryonic antigen; AFP: alpha-fetoprotein; PSA: prostate specific antigen.